Scientists test new drug duo against tough cancers linked to faulty genes
NCT ID NCT06177171
Summary
This is an early-stage study to find a safe and tolerable dose of two oral drugs, olaparib and ASTX727, when given together. It is for adults with advanced solid tumors that have specific mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to check for side effects and determine the best dose for future testing, while also getting an early look at whether the combination can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATM GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.